Pharma Firms Explore Paths to Join Trump-Linked Drug Pricing Discussions
Several pharmaceutical companies are examining whether there may be opportunities to participate in drug-pricing conversations connected to policy approaches discussed during the administration of Donald Trump. While earlier agreements and proposals focused on specific manufacturers and medicines, interest appears to be widening among firms that were not initially part of those frameworks. Industry observers say … Read more